{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T16:28:15Z","timestamp":1781108895483,"version":"3.54.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T00:00:00Z","timestamp":1702598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Cholangiocarcinoma is the most common malignant bile duct tumor in Southeast Asia. The special location of cholangiocarcinoma leads to it being difficult to diagnose. Currently, the progress in clinical prognosis outcomes remains abysmal owing to the lack of definitive diagnostic criteria. Therefore, uncovering the potential markers for cholangiocarcinoma is a pressing issue. Ubiquitin-conjugating enzyme E2 C (UBE2C) is a critical ubiquitination enzyme; it is involved in the tumorigenesis of various malignancies and affects the patient\u2019s prognosis. However, there is currently no relevant literature to indicate whether UBE2C is related to the clinical survival outcome of cholangiocarcinoma patients. In this report, we mined the published cholangiocarcinoma transcriptome data set (GSE26566), compared it with the ubiquitination-associated gene (GO:0016567), and identified that UBE2C was highly expressed in cholangiocarcinoma tumor tissue. Moreover, high expression of UBE2C was markedly correlated with surgical margin, primary tumor, histological variants, and histological grade. More specifically, high expression of UBE2C was negatively associated with overall survival, disease-specific survival, local recurrence-free survival, and metastasis-free survival in patients with cholangiocarcinoma. Our findings demonstrate that UBE2C may provide a potential therapeutic marker and prognostic factor for cholangiocarcinoma patients.<\/jats:p>","DOI":"10.1186\/s40001-023-01575-9","type":"journal-article","created":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T16:02:44Z","timestamp":1702656164000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Ubiquitin-conjugating enzyme E2C (UBE2C) is a prognostic indicator for cholangiocarcinoma"],"prefix":"10.1186","volume":"28","author":[{"given":"Khaa Hoo","family":"Ong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Yue","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ding-Ping","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzu-Ju","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven Kuan-Hua","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Feng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Lin","family":"Chou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yow-Ling","family":"Shiue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ti-Chun","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Feng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hsuan","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,15]]},"reference":[{"issue":"12","key":"1575_CR1","doi-asserted-by":"publisher","first-page":"738","DOI":"10.21037\/atm.2020.03.167","volume":"8","author":"CT Aquina","year":"2020","unstructured":"Aquina CT, Pawlik TM, Ejaz A. Cholangiocarcinoma: three different entities based on location. Ann Transl Med. 2020;8(12):738.","journal-title":"Ann Transl Med"},{"key":"1575_CR2","doi-asserted-by":"publisher","first-page":"309","DOI":"10.3389\/fgene.2018.00309","volume":"9","author":"MS Shiao","year":"2018","unstructured":"Shiao MS, Chiablaem K, Charoensawan V, Ngamphaiboon N, Jinawath N. Emergence of intrahepatic cholangiocarcinoma: how high-throughput technologies expedite the solutions for a rare cancer type. Front Genet. 2018;9:309.","journal-title":"Front Genet"},{"key":"1575_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2460\/javma.21.12.0514","volume":"260","author":"K Terai","year":"2022","unstructured":"Terai K, Ishigaki K, Kagawa Y, Okada K, Yoshida O, Sakurai N, et al. Clinical, diagnostic, and pathologic features and surgical outcomes of combined hepatocellular-cholangiocarcinoma in dogs: 14 cases (2009\u20132021). J Am Vet Med Assoc. 2022;260:1\u20137.","journal-title":"J Am Vet Med Assoc"},{"issue":"9","key":"1575_CR4","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1038\/s41575-020-0310-z","volume":"17","author":"JM Banales","year":"2020","unstructured":"Banales JM, Marin JJG, Lamarca A, Rodrigues PM, Khan SA, Roberts LR, et al. Cholangiocarcinoma 2020: the next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020;17(9):557\u201388.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1575_CR5","doi-asserted-by":"publisher","first-page":"13","DOI":"10.2147\/IJGM.S186854","volume":"12","author":"M Alsaleh","year":"2019","unstructured":"Alsaleh M, Leftley Z, Barbera TA, Sithithaworn P, Khuntikeo N, Loilome W, et al. Cholangiocarcinoma: a guide for the nonspecialist. Int J Gen Med. 2019;12:13\u201323.","journal-title":"Int J Gen Med"},{"key":"1575_CR6","doi-asserted-by":"publisher","first-page":"691380","DOI":"10.3389\/fonc.2021.691380","volume":"11","author":"Y Ding","year":"2021","unstructured":"Ding Y, Han X, Sun Z, Tang J, Wu Y, Wang W. Systemic sequential therapy of CisGem, tislelizumab, and lenvatinib for advanced intrahepatic cholangiocarcinoma conversion therapy. Front Oncol. 2021;11:691380.","journal-title":"Front Oncol"},{"issue":"1","key":"1575_CR7","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12876-018-0912-x","volume":"18","author":"KM Chan","year":"2018","unstructured":"Chan KM, Tsai CY, Yeh CN, Yeh TS, Lee WC, Jan YY, et al. Characterization of intrahepatic cholangiocarcinoma after curative resection: outcome, prognostic factor, and recurrence. BMC Gastroenterol. 2018;18(1):180.","journal-title":"BMC Gastroenterol"},{"key":"1575_CR8","doi-asserted-by":"publisher","first-page":"604387","DOI":"10.3389\/fonc.2020.604387","volume":"10","author":"E Gkika","year":"2020","unstructured":"Gkika E, Hawkins MA, Grosu AL, Brunner TB. The evolving role of radiation therapy in the treatment of biliary tract cancer. Front Oncol. 2020;10:604387.","journal-title":"Front Oncol"},{"issue":"7","key":"1575_CR9","doi-asserted-by":"publisher","first-page":"3440","DOI":"10.3390\/ijms22073440","volume":"22","author":"X Du","year":"2021","unstructured":"Du X, Song H, Shen N, Hua R, Yang G. The molecular basis of ubiquitin-conjugating enzymes (E2s) as a potential target for cancer therapy. Int J Mol Sci. 2021;22(7):3440.","journal-title":"Int J Mol Sci"},{"issue":"10","key":"1575_CR10","doi-asserted-by":"publisher","first-page":"2176","DOI":"10.7150\/jca.32731","volume":"10","author":"G Liu","year":"2019","unstructured":"Liu G, Zhao J, Pan B, Ma G, Liu L. UBE2C overexpression in melanoma and its essential role in G2\/M transition. J Cancer. 2019;10(10):2176\u201384.","journal-title":"J Cancer"},{"issue":"14","key":"1575_CR11","first-page":"4167","volume":"63","author":"Y Okamoto","year":"2003","unstructured":"Okamoto Y, Ozaki T, Miyazaki K, Aoyama M, Miyazaki M, Nakagawara A. UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme. Cancer Res. 2003;63(14):4167\u201373.","journal-title":"Cancer Res"},{"issue":"9","key":"1575_CR12","first-page":"1044","volume":"45","author":"Y Liu","year":"2020","unstructured":"Liu Y, Huang F, Chen H, Peng Q, Zhao C, Miao L. Expression of UBE2C in lung adenocarcinoma based on database analysis and its clinical significance. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2020;45(9):1044\u201352.","journal-title":"Zhong Nan Da Xue Xue Bao Yi Xue Ban"},{"issue":"1","key":"1575_CR13","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1186\/s12885-021-08634-6","volume":"21","author":"R Li","year":"2021","unstructured":"Li R, Pang XF, Huang ZG, Yang LH, Peng ZG, Ma J, et al. Overexpression of UBE2C in esophageal squamous cell carcinoma tissues and molecular analysis. BMC Cancer. 2021;21(1):996.","journal-title":"BMC Cancer"},{"issue":"1","key":"1575_CR14","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1002\/ijc.22605","volume":"121","author":"K Ieta","year":"2007","unstructured":"Ieta K, Ojima E, Tanaka F, Nakamura Y, Haraguchi N, Mimori K, et al. Identification of overexpressed genes in hepatocellular carcinoma, with special reference to ubiquitin-conjugating enzyme E2C gene expression. Int J Cancer. 2007;121(1):33\u20138.","journal-title":"Int J Cancer"},{"key":"1575_CR15","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1186\/1471-2407-13-192","volume":"13","author":"Z Shen","year":"2013","unstructured":"Shen Z, Jiang X, Zeng C, Zheng S, Luo B, Zeng Y, et al. High expression of ubiquitin-conjugating enzyme 2C (UBE2C) correlates with nasopharyngeal carcinoma progression. BMC Cancer. 2013;13:192.","journal-title":"BMC Cancer"},{"key":"1575_CR16","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/j.biopha.2017.08.095","volume":"95","author":"T Qin","year":"2017","unstructured":"Qin T, Huang G, Chi L, Sui S, Song C, Li N, et al. Exceptionally high UBE2C expression is a unique phenomenon in basal-like type breast cancer and is regulated by BRCA1. Biomed Pharmacother. 2017;95:649\u201355.","journal-title":"Biomed Pharmacother"},{"issue":"46","key":"1575_CR17","doi-asserted-by":"publisher","first-page":"e17896","DOI":"10.1097\/MD.0000000000017896","volume":"98","author":"Y Gong","year":"2019","unstructured":"Gong Y, Wang D, Lin L, Dai J, Yu L. The expression of ubiquitin-conjugating enzyme E2C and KAI1 in ovarian carcinoma and their clinical significance. Medicine. 2019;98(46):e17896.","journal-title":"Medicine"},{"issue":"2","key":"1575_CR18","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1158\/1541-7786.MCR-19-0561","volume":"18","author":"Y Liu","year":"2020","unstructured":"Liu Y, Zhao R, Chi S, Zhang W, Xiao C, Zhou X, et al. UBE2C is upregulated by estrogen and promotes epithelial-mesenchymal transition via p53 in endometrial cancer. Mol Cancer Res. 2020;18(2):204\u201315.","journal-title":"Mol Cancer Res"},{"key":"1575_CR19","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.3389\/fonc.2019.01574","volume":"9","author":"YJ Kim","year":"2019","unstructured":"Kim YJ, Lee G, Han J, Song K, Choi JS, Choi YL, et al. UBE2C overexpression aggravates patient outcome by promoting estrogen-dependent\/independent cell proliferation in early hormone receptor-positive and HER2-negative breast cancer. Front Oncol. 2019;9:1574.","journal-title":"Front Oncol"},{"issue":"1","key":"1575_CR20","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1038\/s41420-022-00935-4","volume":"8","author":"C Xiang","year":"2022","unstructured":"Xiang C, Yan HC. Ubiquitin conjugating enzyme E2 C (UBE2C) may play a dual role involved in the progression of thyroid carcinoma. Cell Death Discov. 2022;8(1):130.","journal-title":"Cell Death Discov"},{"issue":"1","key":"1575_CR21","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3390\/biom11010037","volume":"11","author":"AJ Chiang","year":"2020","unstructured":"Chiang AJ, Li CJ, Tsui KH, Chang C, Chang YI, Chen LW, et al. UBE2C drives human cervical cancer progression and is positively modulated by mTOR. Biomolecules. 2020;11(1):37.","journal-title":"Biomolecules"},{"issue":"6","key":"1575_CR22","first-page":"1665","volume":"22","author":"HQ Zhang","year":"2018","unstructured":"Zhang HQ, Zhao G, Ke B, Ma G, Liu GL, Liang H, et al. Overexpression of UBE2C correlates with poor prognosis in gastric cancer patients. Eur Rev Med Pharmacol Sci. 2018;22(6):1665\u201371.","journal-title":"Eur Rev Med Pharmacol Sci"},{"issue":"25","key":"1575_CR23","doi-asserted-by":"publisher","first-page":"11775","DOI":"10.7150\/thno.51655","volume":"10","author":"TC Chan","year":"2020","unstructured":"Chan TC, Wu WJ, Li WM, Shiao MS, Shiue YL, Li CF. SLC14A1 prevents oncometabolite accumulation and recruits HDAC1 to transrepress oncometabolite genes in urothelial carcinoma. Theranostics. 2020;10(25):11775\u201393.","journal-title":"Theranostics"},{"issue":"1","key":"1575_CR24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13244-021-01147-7","volume":"13","author":"J Liu","year":"2022","unstructured":"Liu J, Ren WX, Shu J. Multimodal molecular imaging evaluation for early diagnosis and prognosis of cholangiocarcinoma. Insights Imaging. 2022;13(1):10.","journal-title":"Insights Imaging"},{"issue":"7","key":"1575_CR25","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1097\/CM9.0000000000001474","volume":"134","author":"W Cao","year":"2021","unstructured":"Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J (Engl). 2021;134(7):783\u201391.","journal-title":"Chin Med J (Engl)"},{"issue":"1","key":"1575_CR26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.21037\/hbsn.2016.11.04","volume":"6","author":"S Vijgen","year":"2017","unstructured":"Vijgen S, Terris B, Rubbia-Brandt L. Pathology of intrahepatic cholangiocarcinoma. Hepatobiliary Surg Nutr. 2017;6(1):22\u201334.","journal-title":"Hepatobiliary Surg Nutr"},{"key":"1575_CR27","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/bs.acr.2020.10.005","volume":"149","author":"AE Sirica","year":"2021","unstructured":"Sirica AE, Strazzabosco M, Cadamuro M. Intrahepatic cholangiocarcinoma: morpho-molecular pathology, tumor reactive microenvironment, and malignant progression. Adv Cancer Res. 2021;149:321\u201387.","journal-title":"Adv Cancer Res"},{"issue":"4","key":"1575_CR28","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s00534-005-1055-3","volume":"13","author":"I Tischoff","year":"2006","unstructured":"Tischoff I, Wittekind C, Tannapfel A. Role of epigenetic alterations in cholangiocarcinoma. J Hepatobiliary Pancreat Surg. 2006;13(4):274\u20139.","journal-title":"J Hepatobiliary Pancreat Surg"},{"issue":"2","key":"1575_CR29","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.celrep.2018.12.066","volume":"26","author":"P Jia","year":"2019","unstructured":"Jia P, Zhao Z. Characterization of tumor-suppressor gene inactivation events in 33 cancer types. Cell Rep. 2019;26(2):496-506 e3.","journal-title":"Cell Rep"},{"issue":"Suppl 1","key":"1575_CR30","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/liv.14095","volume":"39","author":"SA Khan","year":"2019","unstructured":"Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: epidemiology and risk factors. Liver Int. 2019;39(Suppl 1):19\u201331.","journal-title":"Liver Int"},{"issue":"6","key":"1575_CR31","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.3390\/cancers14061442","volume":"14","author":"L Ceci","year":"2022","unstructured":"Ceci L, Zhou T, Lenci I, Meadows V, Kennedy L, Li P, et al. Molecular mechanisms linking risk factors to cholangiocarcinoma development. Cancers. 2022;14(6):1442.","journal-title":"Cancers"},{"issue":"11","key":"1575_CR32","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1016\/j.dld.2020.06.045","volume":"52","author":"WG Cholangiocarcinoma","year":"2020","unstructured":"Cholangiocarcinoma WG. Italian clinical practice guidelines on cholangiocarcinoma\u2014part I: classification, diagnosis and staging. Dig Liver Dis. 2020;52(11):1282\u201393.","journal-title":"Dig Liver Dis"},{"issue":"Suppl 1","key":"1575_CR33","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1111\/liv.14086","volume":"39","author":"A Forner","year":"2019","unstructured":"Forner A, Vidili G, Rengo M, Bujanda L, Ponz-Sarvise M, Lamarca A. Clinical presentation, diagnosis and staging of cholangiocarcinoma. Liver Int. 2019;39(Suppl 1):98\u2013107.","journal-title":"Liver Int"},{"issue":"4","key":"1575_CR34","doi-asserted-by":"publisher","first-page":"188","DOI":"10.3390\/genes9040188","volume":"9","author":"P Nicolau-Neto","year":"2018","unstructured":"Nicolau-Neto P, Palumbo A, De Martino M, Esposito F, de Almeida ST, Fusco A, et al. UBE2C is a transcriptional target of the cell cycle regulator FOXM1. Genes. 2018;9(4):188.","journal-title":"Genes"},{"issue":"4","key":"1575_CR35","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.3892\/ijo.2017.3880","volume":"50","author":"R Wang","year":"2017","unstructured":"Wang R, Song Y, Liu X, Wang Q, Wang Y, Li L, et al. UBE2C induces EMT through Wnt\/betacatenin and PI3K\/Akt signaling pathways by regulating phosphorylation levels of Aurora-A. Int J Oncol. 2017;50(4):1116\u201326.","journal-title":"Int J Oncol"},{"issue":"2","key":"1575_CR36","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbrc.2019.12.064","volume":"523","author":"Z Jin","year":"2020","unstructured":"Jin Z, Zhao X, Cui L, Xu X, Zhao Y, Younai F, et al. UBE2C promotes the progression of head and neck squamous cell carcinoma. Biochem Biophys Res Commun. 2020;523(2):389\u201397.","journal-title":"Biochem Biophys Res Commun"},{"issue":"5","key":"1575_CR37","doi-asserted-by":"publisher","first-page":"956","DOI":"10.4254\/wjh.v14.i5.956","volume":"14","author":"CY Zhang","year":"2022","unstructured":"Zhang CY, Yang M. Functions of three ubiquitin-conjugating enzyme 2 genes in hepatocellular carcinoma diagnosis and prognosis. World J Hepatol. 2022;14(5):956\u201371.","journal-title":"World J Hepatol"},{"issue":"3","key":"1575_CR38","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10549-022-06531-5","volume":"192","author":"Y Kariri","year":"2022","unstructured":"Kariri Y, Toss MS, Alsaleem M, Elsharawy KA, Joseph C, Mongan NP, et al. Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer. Breast Cancer Res Treat. 2022;192(3):529\u201339.","journal-title":"Breast Cancer Res Treat"},{"issue":"11","key":"1575_CR39","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.tibs.2005.09.005","volume":"30","author":"M Malumbres","year":"2005","unstructured":"Malumbres M, Barbacid M. Mammalian cyclin-dependent kinases. Trends Biochem Sci. 2005;30(11):630\u201341.","journal-title":"Trends Biochem Sci"},{"key":"1575_CR40","doi-asserted-by":"publisher","first-page":"e925289","DOI":"10.12659\/MSM.925289","volume":"26","author":"Y Zou","year":"2020","unstructured":"Zou Y, Ruan S, Jin L, Chen Z, Han H, Zhang Y, et al. CDK1, CCNB1, and CCNB2 are prognostic biomarkers and correlated with immune infiltration in hepatocellular carcinoma. Med Sci Monit. 2020;26:e925289.","journal-title":"Med Sci Monit"},{"issue":"4","key":"1575_CR41","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1038\/ncb3323","volume":"18","author":"A Suzuki","year":"2016","unstructured":"Suzuki A, Badger BL, Haase J, Ohashi T, Erickson HP, Salmon ED, et al. How the kinetochore couples microtubule force and centromere stretch to move chromosomes. Nat Cell Biol. 2016;18(4):382\u201392.","journal-title":"Nat Cell Biol"},{"issue":"4","key":"1575_CR42","first-page":"1233","volume":"12","author":"X Chen","year":"2019","unstructured":"Chen X, Li W, Xiao L, Liu L. Nuclear division cycle 80 complex is associated with malignancy and predicts poor survival of hepatocellular carcinoma. Int J Clin Exp Pathol. 2019;12(4):1233\u201347.","journal-title":"Int J Clin Exp Pathol"},{"issue":"20","key":"1575_CR43","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.3748\/wjg.v23.i20.3675","volume":"23","author":"LL Ju","year":"2017","unstructured":"Ju LL, Chen L, Li JH, Wang YF, Lu RJ, Bian ZL, et al. Effect of NDC80 in human hepatocellular carcinoma. World J Gastroenterol. 2017;23(20):3675\u201383.","journal-title":"World J Gastroenterol"},{"issue":"54","key":"1575_CR44","doi-asserted-by":"publisher","first-page":"93014","DOI":"10.18632\/oncotarget.21745","volume":"8","author":"D Zhang","year":"2017","unstructured":"Zhang D, Liu E, Kang J, Yang X, Liu H. MiR-3613-3p affects cell proliferation and cell cycle in hepatocellular carcinoma. Oncotarget. 2017;8(54):93014\u201328.","journal-title":"Oncotarget"},{"issue":"14","key":"1575_CR45","doi-asserted-by":"publisher","first-page":"5241","DOI":"10.7150\/ijbs.71694","volume":"18","author":"J Yang","year":"2022","unstructured":"Yang J, Huang Y, Song M, Pan Q, Zhao J, He J, et al. SPC25 promotes proliferation and stemness of hepatocellular carcinoma cells via the DNA-PK\/AKT\/Notch1 signaling pathway. Int J Biol Sci. 2022;18(14):5241\u201359.","journal-title":"Int J Biol Sci"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-023-01575-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-023-01575-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-023-01575-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,15]],"date-time":"2023-12-15T16:05:31Z","timestamp":1702656331000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-023-01575-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,15]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1575"],"URL":"https:\/\/doi.org\/10.1186\/s40001-023-01575-9","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,15]]},"assertion":[{"value":"22 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 December 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"As a rule, every participant signed informed consent before samples were deposited in the biobank. This study and its use of deidentified tumor samples from the biobank were approved by the Ethics Committee and Institutional Review Board of Chi Mei Medical Center (IRB No.09912003). This study was conducted following the ethical guidelines of the Declaration of Helsinki and the regulations of our government.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that the research was conducted in the absence of any commercial or financial relationship that could be construed as a potential competing interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"593"}}